betnesol-n 0.1% w/v, 3500 iu/ml eye, ear and nasal drops, solution
rph pharmaceuticals ab - neomycin sulfate; betamethasone sodium phosphate - ear/eye/nasal drops, solution - 0.1% w/v 3500 international unit(s)/millilitre - corticosteroids and antiinfectives in combination; betamethasone and antiinfectives
celestovet soluspan suspension betamethasone sodium phosphate
novartis animal health australasia pty. limited - betamethasone acetate | betamethasone sodium phosphate - anti-inflammatory
celestone soluspan
msd (pty) ltd - betamethasone disodium phosphate, betamethasone acetate - suspension - betamethasone disodium phosphate (solution) 3.0mg and betamethasone acetate (suspension) 3.0mg /ml
betamethasone dipropionate cream
actavis pharma, inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 g - betamethasone dipropionate cream is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years and older. betamethasone dipropionate cream is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
betamethasone dipropionate cream
taro pharmaceuticals u.s.a., inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone dipropionate 0.64 mg in 1 g - betamethasone dipropionate cream is a medium-potency corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 13 years and older. betamethasone dipropionate cream is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation.
betamethasone dipropionate lotion, augmented
taro pharmaceuticals u.s.a., inc. - betamethasone dipropionate (unii: 826y60901u) (betamethasone - unii:9842x06q6m) - betamethasone 0.5 mg in 1 ml - betamethasone dipropionate lotion (augmented) is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older. betamethasone dipropionate lotion (augmented), 0.05% is contraindicated in patients who are hypersensitive to betamethasone dipropionate, to other corticosteroids, or to any ingredient in this preparation. risk summary there are no available data on betamethasone dipropionate lotion (augmented) use in pregnant women to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. observational studies suggest an increased risk of low birthweight infants with the use of greater than 300 grams of potent or very potent topical corticosteroid during a pregnancy. advise pregnant women that betamethasone dipropionate lotion (augmented) may increase the risk of having a low birthweight infant and to use betamethasone dipropionate lotion (augmented) on the sm
betamethasone valerate cream
rebel distributors corp. - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - betamethasone valerate 1 mg in 1 g - betamethasone valerate cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. betamethasone valerate cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
orapred odt- prednisolone sodium phosphate tablet, orally disintegrating
concordia pharmaceuticals inc. - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone 10 mg - orapred odt (prednisolone sodium phosphate orally disintegrating tablet) is indicated in the treatment of the following diseases or conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: - atopic dermatitis - drug hypersensitivity reactions - seasonal or perennial allergic rhinitis - serum sickness - bullous dermatitis herpetiformis - contact dermatitis - exfoliative erythroderma - mycosis fungoides - pemphigus - severe erythema multiforme (stevens-johnson syndrome) - congenital adrenal hyperplasia - hypercalcemia of malignancy - nonsuppurative thyroiditis - primary or secondary adrenocortical insufficiency: hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable. during acute episodes in: - crohn's disease - ulcerative colitis - acquired (autoimmune) hemolytic anemia - diamond-blackfan anemia - idiopathic thrombocytopenic
prednisolone sodium phosphate solution
lohxa - prednisolone sodium phosphate (unii: iv021nxa9j) (prednisolone - unii:9phq9y1olm) - prednisolone sodium phosphate oral solution (15 mg prednisolone per 5 ml) is indicated in the following conditions: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (stevens-johnson syndrome); exfoliative erythroderma; mycosis fungoides. to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital ad
betacin eye/ear drops
duopharma (m) sdn. bhd. - betamethasone sodium phosphate; neomycin sulphate -